![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Therapeutics Reports Second Quarter 2015 Financial Results
12 août 2015 16h05 HE
|
Juno Therapeutics
-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial --
-- Transformative partnership with Celgene --
-- Substantial R&D progress with key acquisition integrations on...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Therapeutics to Report Second Quarter 2015 Financial Results on Wednesday, August 12
05 août 2015 16h05 HE
|
Juno Therapeutics
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the second quarter of 2015 on Wednesday, August 12, 2015 after the close of...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Announces Early HSR Clearance for Global Collaboration With Celgene
05 août 2015 08h00 HE
|
Juno Therapeutics
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
30 juil. 2015 16h39 HE
|
Juno Therapeutics
-- Multi-center, pivotal Phase 2 trial to begin in the near term --
SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Announces FDA Acceptance of Investigational New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
29 juin 2015 08h00 HE
|
Juno Therapeutics
SEATTLE, June 29, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Therapeutics to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
03 juin 2015 08h00 HE
|
Juno Therapeutics
SEATTLE, June 3, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the Goldman Sachs 36th Annual Global Healthcare Conference at...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Therapeutics Adds Antibody Engineering Capabilities Through Acquisition of X-BODY
02 juin 2015 07h30 HE
|
Juno Therapeutics
-- Transaction Accelerates Capabilities to Create Novel Fully Human CAR T and TCR Constructs --
-- Initial Payment of Approximately $21 Million in Cash and 439,265 Shares of Juno Stock...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno's Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses and Translational Insights in Patients With B-Cell Cancers
01 juin 2015 08h00 HE
|
Juno Therapeutics
SEATTLE, June 1, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. announced today that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses in Patients With B-Cell Cancers
30 mai 2015 14h20 HE
|
Juno Therapeutics
SEATTLE, May 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) announced today that clinical data from its most advanced chimeric antigen receptor (CAR) T cell product candidate,...
![Juno Therapeutics Company Logo](/news-release/logo/326601/0/326601.jpg?lastModified=12%2F09%2F2016%2023%3A59%3A56&size=2)
Juno Therapeutics Appoints Dr. Hyam I. Levitsky as Chief Scientific Officer
28 mai 2015 16h01 HE
|
Juno Therapeutics
SEATTLE, May 28, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...